SEC Comment Letter 0000000000-24-012471 to Bio Essence Corp (BIOE)
Bio Essence Corp
Date: Nov. 8, 2024 · CIK: 0001723059 · Accession: 0000000000-24-012471
AI Filing Summary & Sentiment
File numbers found in text: 000-56263
Letter
November 8, 2024 Yin Yan Chief Executive Officer Bio Essence Corp 12 Chrysler, Unit B Irvine, CA 92618 Re:Bio Essence Corp Form 10-K for Fiscal Year Ended December 31, 2023 Amendment No. 2 to Form 10-Q for Quarterly Period Ended March 31, 2024 File No. 000-56263 Dear Yin Yan: We have reviewed your Amendment No. 2 to Form 10-Q for the Quarterly Period Ended March 31, 2024 in response to our comment letter and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our October 21, 2024 letter. Amendment No. 2 to Form 10-Q for Quarterly Period Ended March 31, 2024 Item 4. Controls and Procedures, page 23 1.We note the revised conclusions regarding internal control over financial reporting within both amended Form 10-Qs provided in response to our comment. However, we do not see any revisions to your conclusion regarding disclosure controls and procedures. Please tell us how you determined that your disclosure controls and procedures as of March 31, 2024 and June 30, 2024 are effective considering the restatement and the amendments to your filings.
November 8, 2024 Page 2 Please contact Lynn Dicker at 202-551-3616 or Eric Atallah at 202-551-3663 if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
November 8, 2024
Yin Yan
Chief Executive Officer
Bio Essence Corp
12 Chrysler, Unit B
Irvine, CA 92618
Re:Bio Essence Corp
Form 10-K for Fiscal Year Ended December 31, 2023
Amendment No. 2 to Form 10-Q for Quarterly Period Ended March 31, 2024
File No. 000-56263
Dear Yin Yan:
We have reviewed your Amendment No. 2 to Form 10-Q for the Quarterly Period
Ended March 31, 2024 in response to our comment letter and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Unless we note otherwise, any references to prior comments are to comments in our October
21, 2024 letter.
Amendment No. 2 to Form 10-Q for Quarterly Period Ended March 31, 2024
Item 4. Controls and Procedures, page 23
1.We note the revised conclusions regarding internal control over financial reporting
within both amended Form 10-Qs provided in response to our comment. However, we
do not see any revisions to your conclusion regarding disclosure controls and
procedures. Please tell us how you determined that your disclosure controls and
procedures as of March 31, 2024 and June 30, 2024 are effective considering the
restatement and the amendments to your filings.
November 8, 2024
Page 2
Please contact Lynn Dicker at 202-551-3616 or Eric Atallah at 202-551-3663 if you
have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Life Sciences